Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema

Nonsteroidal anti-inflammatory drugs (NSAIDs) are nowadays widely used in ophthalmology to reduce eye inflammation, pain, and cystoid macular edema associated with cataract surgery. Recently, new topical NSAIDs have been approved for topical ophthalmic use, allowing for greater drug penetration into the vitreous. Hence, new therapeutic effects can be achieved, such as reduction of exudation secondary to age-related macular degeneration or diabetic maculopathy. We provide an updated review on the clinical use of NSAIDs for retinal diseases, with a focus on the potential future applications.

• Publication year

  2013

• Venue

  Mediators of Inflammation

• Publication date

  2013-10-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2013/476525PMID 24227908PMCID 3818914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The association of aspirin use with age-related macular degeneration.

  2013cited by this paper
• A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration

  2013cited by this paper
• Effects of Aspirin Treatment on Diabetic Retinopathy

  2013cited by this paper
• Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.

  2013cited by this paper
• 24-hour intraocular pressure and ocular perfusion pressure in glaucoma.

  2013cited by this paper
• Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease

  2013influential reference
• Aqueous flare is increased in patients with clinically significant cystoid macular oedema after cataract surgery

  2013influential reference
• PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study

  2012influential reference
• Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery.

  2012cited by this paper
• Diabetic retinopathy.

  2012cited by this paper
• I and J

  2012cited by this paper
• Mechanism of Inflammation in Age-Related Macular Degeneration

  2012influential reference
• A Randomized Controlled Trial of a Tailored Primary Care Program to Reverse Excessive Alcohol Consumption

  2012cited by this paper
• “Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema”.

  2012cited by this paper
• Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification

  2012cited by this paper
• TOPICAL BROMFENAC AS AN ADJUNCTIVE TREATMENT WITH INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION

  2012influential reference
• Associations between aspirin use and aging macula disorder: the European Eye Study.

  2012influential reference
• Role of Intravitreal Inflammatory Cytokines and Angiogenic Factors in Proliferative Diabetic Retinopathy

  2012cited by this paper
• Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration

  2012cited by this paper
• Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines.

  2012cited by this paper
• Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review

  2011cited by this paper
• A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification

  2011cited by this paper
• INTRAVITREAL DICLOFENAC VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF DIABETIC MACULAR EDEMA

  2011cited by this paper
• Long-term outcome and patterns of failure in patients with advanced head and neck cancer

  2011cited by this paper
• The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment

  2011cited by this paper
• Prostaglandin E2 Inhibition of Ketorolac 0.45%, Bromfenac 0.09%, and Nepafenac 0.1% in Patients Undergoing Phacoemulsification

  2011cited by this paper
• Postsurgical Cystoid Macular Edema

  2011cited by this paper
• Intravitreal Injection of Commercially Available Ketorolac Tromethamine in Eyes with Diabetic Macular Edema Refractory to Laser Photocoagulation

  2011cited by this paper
• [Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation].

  2010cited by this paper
• Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology

  2010cited by this paper
• PILOT STUDY OF INTRAVITREAL INJECTION OF DICLOFENAC FOR TREATMENT OF MACULAR EDEMA OF VARIOUS ETIOLOGIES

  2010cited by this paper
• NSAIDS IN COMBINATION THERAPY FOR THE TREATMENT OF CHRONIC PSEUDOPHAKIC CYSTOID MACULAR EDEMA

  2010cited by this paper
• Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF.

  2010cited by this paper
• Investigative Ophthalmology and Visual Science

  2010cited by this paper
• PRELIMINARY ASSESSMENT OF CELECOXIB AND MICRODIODE PULSE LASER TREATMENT OF DIABETIC MACULAR EDEMA

  2010cited by this paper
• Nonsteroidal anti-inflammatory drugs in ophthalmology.

  2010cited by this paper
• Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells.

  2010cited by this paper
• Inhibition of choroidal neovascularization by intravitreal ketorolac.

  2010cited by this paper
• Postsurgical cystoid macular edema.

  2010cited by this paper
• RETROSPECTIVE REVIEW OF THE EFFICACY OF TOPICAL BROMFENAC (0.09%) AS AN ADJUNCTIVE THERAPY FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

  2009cited by this paper
• Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%

  2009influential reference
• [Epidemiology of age related macular degeneration].

  2009cited by this paper
• VITREOUS NONSTEROIDAL ANTIINFLAMMATORY DRUG CONCENTRATIONS AND PROSTAGLANDIN E2 LEVELS IN VITRECTOMY PATIENTS TREATED WITH KETOROLAC 0.4%, BROMFENAC 0.09%, AND NEPAFENAC 0.1%

  2009cited by this paper
• Autoimmunity in retinal degeneration: autoimmune retinopathy and age-related macular degeneration.

  2009cited by this paper
• EXPRESSION OF CYCLOOXYGENASE-2 IN CHOROIDAL NEOVASCULAR MEMBRANES FROM AGE-RELATED MACULAR DEGENERATION PATIENTS

  2009cited by this paper
• The role of PGE2 receptor EP4 in pathologic ocular angiogenesis.

  2009cited by this paper
• Optical coherence tomography and cataract surgery

  2009cited by this paper
• Topical nepafenac in the treatment of diabetic macular edema

  2008influential reference
• Topical and Oral Ketorolac Administration Increases the Intraocular Pressure-Lowering Effect of Latanoprost

  2008cited by this paper
• A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients.

  2008cited by this paper
• Immunopathological aspects of age-related macular degeneration

  2008cited by this paper
• Immunological mechanisms in the pathogenesis of diabetic retinopathy

  2008cited by this paper
• Topical Ocular Delivery of NSAIDs

  2008cited by this paper
• Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial.

  2008cited by this paper
• The effect of long-term treatment with sulindac on the progression of diabetic retinopathy*

  2007cited by this paper
• Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery: Prospective randomized double‐masked clinical trial

  2007cited by this paper
• Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.

  2007cited by this paper
• Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography.

  2007cited by this paper
• Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.

  2007cited by this paper
• Topical Administration of Nepafenac Inhibits Diabetes-Induced Retinal Microvascular Disease and Underlying Abnormalities of Retinal Metabolism and Physiology

  2007cited by this paper
• In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac

  2007cited by this paper
• Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery

  2007cited by this paper
• Influence of cultivation temperature on the ligninolytic activity of selected fungal strains

  2006influential reference
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration.

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Systematic review and meta-analysis of the association between complementary factor HY402H polymorphisms and age-related macular degeneration

  2006cited by this paper
• Celecoxib

  2006cited by this paper
• The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment.

  2006cited by this paper
• Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium*

  2006cited by this paper
• Systematic review and meta-analysis of the association between complementary factor H Y402H polymorphisms and age-related macular degeneration

  2006cited by this paper
• Complement Factor H Polymorphism and Age-Related Macular Degeneration

  2005cited by this paper
• Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization.

  2005cited by this paper
• Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction

  2005cited by this paper
• Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back.

  2005cited by this paper
• Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration

  2005cited by this paper
• Sparing of age-related macular degeneration in rheumatoid arthritis.

  2005cited by this paper
• The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.

  2005cited by this paper
• Complement Factor H Polymorphism in Age-Related Macular Degeneration

  2005cited by this paper
• Role of Complement and Complement Membrane Attack Complex in Laser-Induced Choroidal Neovascularization1

  2005cited by this paper
• Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration.

  2004cited by this paper
• Current concepts in the pathogenesis of age-related macular degeneration.

  2004cited by this paper
• Autoantibodies to retinal astrocytes associated with age-related macular degeneration

  2004cited by this paper
• COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model.

  2004cited by this paper
• The epidemiology of age-related macular degeneration.

  2004cited by this paper
• Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration.

  2004cited by this paper
• Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error?--Not as easy as 1, 2, 3.

  2004cited by this paper
• Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats.

  2004cited by this paper
• Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

  2004cited by this paper
• Macular alterations after small‐incision cataract surgery

  2004influential reference
• Topical Nonsteroidal Anti-Inflammatory Therapy in Ophthalmology

  2003cited by this paper
• Carboxyethylpyrrole Protein Adducts and Autoantibodies, Biomarkers for Age-related Macular Degeneration*

  2003cited by this paper
• Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model.

  2003cited by this paper
• Macular edema reflects generalized vascular hyperpermeability in type 2 diabetic patients with retinopathy.

  2002cited by this paper
• Topical Nonsteroidal Antiinflammatory Drugs in Ophthalmology

  2002cited by this paper
• Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppression

  2002cited by this paper
• Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders.

  2002cited by this paper
• Anatomy and examination of the eyelids.

  2002cited by this paper
• Prostaglandins and cystoid macular edema.

  2002cited by this paper

• Radial Peripapillary Capillary Vessel Density as a New Biomarker in Pseudophakic Cystoid Macular Edema

  2025influential citation
• Indomethacin-incorporated microemulsion-laden contact lenses for improved ocular drug delivery and therapeutic efficacy

  2025cites this paper
• Optimizing Perioperative Management Strategies in Uveitic Cataract Surgery: A Survey of Expert Practices

  2025cites this paper
• Scoping review of non-surgical treatment options for macular holes.

  2024cites this paper
• Intravitreal Injections for Macular Edema in Silicone Oil Filled Eyes

  2024cites this paper
• Clinical Outcomes of Topical Bromfenac Combined with Intravitreal Aflibercept Injection for Exudative Age-related Macular Degeneration

  2024cites this paper
• Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review

  2024cites this paper
• Aspirin intake is not associated with diabetic retinopathy and diabetic macular edema: A report from the Fushun diabetic retinopathy cohort study

  2024cites this paper
• Short-Term Effects of Adding Topical Ketorolac to Intravitreal Bevacizumab in Diabetic Macular Edema: A Crossover Randomized Clinical Trial

  2024cites this paper
• Comparison of drugs belonging to the group of ophthalmic non-steroidal anti-inflammatory drugs

  2023cites this paper
• EFFECT OF TOPICAL SODIUM DICLOFENAC AS ADJUVANT TO INTRAVITREAL BEVACIZUMAB INJECTION THERAPY ON VISUAL ACUITY INTRAOCULAR PRESSURE CHANGES IN PATIENTS WITH DIABETIC MACULAR EDEMA

  2023cites this paper
• Dropless Cataract Surgery

  2023cites this paper
• NSAIDs and corticosteroids for the postoperative management of age-related cataract surgery: a systematic review and meta-analysis.

  2023cites this paper
• Preparation of Polycaprolactone and Polymethacrylate Nanofibers for Controlled Ocular Delivery of Ketorolac tromethamine: Pharmacokinetic study in Rabbit's Eye.

  2023cites this paper
• Progressive resolution of exudation from perifoveal vascular anomalous complex: A possible role of diclofenac therapy?

  2022cites this paper
• CPD: Cataract post-op complications

  2022cites this paper
• The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers

  2022cites this paper
• Topical Nanoemulsion of a Runt-related Transcription Factor 1 Inhibitor for the Treatment of Pathologic Ocular Angiogenesis

  2022cites this paper
• A prospective randomized clinical trial of active-fluidics versus gravity-fluidics system in phacoemulsification for age-related cataract (AGSPC)

  2022cites this paper
• A manually made needle for treating Pseudophakic cystoid macular edema by injecting triamcinolone acetonide in the suprachoroidal space: A case report

  2021cites this paper
• Design of ophthalmic micelles loaded with diclofenac sodium: effect of chitosan and temperature on the block-copolymer micellization behaviour

  2021cites this paper
• Cystoid Macular Edema

  2021cites this paper
• Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.

  2020cites this paper
• The Effect of a 0.1% Bromfenac Solution on Diabetic Macular Edema

  2020cites this paper
• Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes

  2020cites this paper
• Incidence of cystoid macular edema following routine cataract surgery using NSAIDs alone or with corticosteroids

  2019influential citation
• Treatment of exudative age‐related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega‐3: A randomized trial

  2019cites this paper
• The evaluation of the effectiveness of intra-articular steroid, tenoxicam, and combined steroid–tenoxicam injections in the treatment of patients with knee osteoarthritis

  2019cites this paper
• Advancing Insights Into Diabetic Eye Disease: 5th Annual American Society of Retina Specialists Presidents’ Young Investigator Award Lecture

  2019cites this paper
• VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.

  2019cites this paper
• Effects of Huangban Bianxing One decoction combined with ranibizumab on treating exudative age-related macular degeneration.

  2019cites this paper
• An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study

  2019cites this paper
• The effect of non-steroidal anti-inflammatory therapy in the correction of the cognitive impairment for patients with chronic cerebral ischemia and metabolic syndrome

  2019cites this paper
• Inner layer‐embedded contact lenses for pH‐triggered controlled ocular drug delivery

  2018cites this paper
• Retinal Vascular Caliber Changes After Topical Nepafenac Treatment for Diabetic Macular Edema

  2018cites this paper
• Difluprednate for the Treatment of Uveitic Cystoid Macular Edema.

  2018cites this paper
• Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification.

  2018cites this paper
• Topical ophthalmic formulations of indomethacin for delivery to the posterior segment ocular tissues

  2017cites this paper
• Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.

  2017cites this paper
• Medical Management of CME Associated with Diabetes

  2017cites this paper
• Bromfenac Eyedrops in the Treatment of Diabetic Macular Edema: A Pilot Study

  2017influential citation
• Chinese medicine formula HB01 for treating exudative age-related macular degeneration: a 6 consecutive months of clinical observation study

  2017cites this paper
• The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy

  2016cites this paper
• Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy

  2016cites this paper
• Diabetic macular oedema: pathophysiology, management challenges and treatment resistance

  2016cites this paper
• Drug, delivery and devices for diabetic retinopathy (3Ds in DR)

  2016cites this paper
• Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.

  2016cites this paper
• REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1%

  2016cites this paper
• Nonbiological pharmacotherapies for the treatment of diabetic macular edema

  2015cites this paper
• Efficacy and vitreous levels of topical NSAIDs

  2015cites this paper
• Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation

  2015cites this paper
• The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery

  2015cites this paper
• TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY

  2015cites this paper
• Ocular safety comparison of non-steroidal anti-inflammatory eye drops used in pseudophakic cystoid macular edema prevention.

  2015cites this paper
• Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant

  2015cites this paper
• Citronellol, a natural acyclic monoterpene, attenuates mechanical hyperalgesia response in mice: Evidence of the spinal cord lamina I inhibition.

  2015cites this paper
• Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis

  2014cites this paper
• Tamponade or Filling Effect: Changes of Forces in Myopic Eyes

  2014cites this paper
• EVALUATION OF RETINOPATHIC POTENTIAL OF FLUOROQUINOLONES

  2014cites this paper
• pharmacotherapeutic approaches for modulating retinal angiogenesis

  2014cites this paper
• EFFECT OF INTRAVITREAL DICLOFENAC ON DIABETIC MACULAR EDEMA WHICH UNRESPONSIVE TO INTRAVITREAL BEVACIZUMAB

  2013cites this paper